Skip to main content
logo
Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.330
+0.010 (0.76%)
Aug 3, 2026, 12:48 PM EDT - Market open

Akebia Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
232.4236.2160.18194.62292.48211.65
Revenue Growth
25.69%47.46%-17.70%-33.46%38.19%-28.17%
Gross Profit
188.28196.7397120.47206.9260.98
Operating Income
5.2923.5-50.47-46.26-80.78-264.5
Net Income
-8.27-5.35-69.41-51.93-94.23-282.02
Earnings Per Share
-0.08-0.02-0.33-0.28-0.52-1.70
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
162.64184.8451.8742.9390.47149.8
Total Debt
48.8948.2542.2443.6395.04131.25
Net Cash (Debt)
113.75136.599.63-0.71-4.5718.55
Net Cash Growth
75.71%1318.42%----87.44%
Net Cash Per Share
0.420.530.05-0.00-0.030.11

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
60.3767.99-40.66-23.38-73.15-252.97
Capital Expenditures
-0.34-0.29-0.03--0.11-0.06
Free Cash Flow
60.0467.7-40.69-23.38-73.27-253.02
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
81.01%83.29%60.56%61.90%70.74%28.81%
Operating Margin
2.28%9.95%-31.51%-23.77%-27.62%-124.97%
Pretax Margin
-8.07%-1.58%-43.33%-26.68%-32.22%-133.25%
Profit Margin
-3.56%-2.26%-43.33%-26.68%-32.22%-133.25%
FCF Margin
25.83%28.66%-25.40%-12.02%-25.05%-119.55%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-82.5618.7218.7218.7218.72
P/FCF Ratio
5.926.31----
PS Ratio
1.531.812.671.240.361.89